Provenance Wealth Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.13M Buy
39,699
+22,615
+132% +$601K 0.07% 145
2026
Q2
$411K Buy
17,084
+359
+2% +$9.39K 0.04% 90
2026
Q1
$470K Hold
16,725
– – 0.05% 75
2025
Q4
$416K Hold
16,725
– – 0.05% 70
2025
Q3
$426K Sell
16,725
-220
-1% -$5.43K 0.06% 75
2025
Q2
$411K Sell
16,945
-6,095
-26% -$142K 0.06% 76
2025
Q1
$584K Sell
23,040
-4,088
-15% -$107K 0.08% 59
2024
Q4
$720K Sell
27,128
-30,644
-53% -$831K 0.09% 62
2024
Q3
$1.67M Buy
57,772
+704
+1% +$20.5K 0.21% 40
2024
Q2
$1.6M Sell
57,068
-300
-0.5% -$8.26K 0.22% 35
2024
Q1
$1.59M Buy
57,368
+16,414
+40% +$455K 0.22% 36
2023
Q4
$1.18M Buy
40,954
+40,105
+4,724% +$1.21M 0.16% 49
2023
Q3
$28.2K Buy
+849
New +$30K ﹤0.01% 206

Other funds holding PFE

Provenance Wealth Advisors's PFE Position: Q3 2026 in Review

Provenance Wealth Advisors increased its Pfizer (PFE) stake by 132% in Q3 2026, buying an estimated $601K and bringing the position to 39,699 shares worth $1.13M. The position accounts for 0.07% of the portfolio, ranked #145.

Provenance Wealth Advisors first reported a position in PFE in Q3 2023 and has held it in 13 quarters since. The position peaked at $1.67M in Q3 2024. 2,920 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Provenance Wealth Advisors held 39,699 shares of Pfizer worth $1.13M as of Q3 2026.
  • Provenance Wealth Advisors bought 22,615 Pfizer shares in Q3 2026, an estimated $601K.
  • Pfizer made up 0.07% of Provenance Wealth Advisors's portfolio in Q3 2026, its #145 holding.
  • Provenance Wealth Advisors first reported a position in Pfizer in Q3 2023 and has held it in 13 quarters since.
  • Provenance Wealth Advisors's Pfizer position peaked at $1.67M in Q3 2024.
  • 2,920 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Provenance Wealth Advisors's 13F filing for Q3 2026, filed 30 Oct 2026.